Emergent closes sale of Baltimore-Bayview facility to Syngene for ~$36.5M

Emergent BioSolutions Inc.

Sale closed on March 19, 2025; Emergent received ~$36.5M at closing, subject to post-closing adjustments.
Syngene acquired assets and equipment of the Baltimore-Bayview drug substance manufacturing site.
Emergent retains rights to secure manufacturing services and capacity at the facility for future growth and pandemic response.
CEO Joe Papa says deal streamlines operations while maintaining flexibility; transaction supports multi-year turnaround.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.